Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

79.83 +1.50 (+1.91%)

Streaming Delayed Price Updated: 1:58 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens

January 02, 2026

As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for...

Via MarketMinute

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Via The Motley Fool

Topics Regulatory Compliance

The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU

January 01, 2026

As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗

December 10, 2025

Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that.

Via The Motley Fool

Topics Artificial Intelligence

Maplebear, Tower Semiconductor, And Eli Lilly Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 10-Nov. 14): Are the Others in Your Portfolio? ↗

November 16, 2025

Ten large-cap standouts—including Maplebear, Tower Semiconductor, Eli Lilly, On Holding, Albemarle, and key gold/silver miners—rallied last week on strong earnings, upbeat guidance, analyst upgrades,...

Via Benzinga

Revolution Medicines (RVMD) Earnings Transcript ↗

November 05, 2025

Revolution Medicines (RVMD) Earnings Transcript

Via The Motley Fool

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement ↗

October 23, 2025

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

A Glimpse of Revolution Medicines's Earnings Potential ↗

May 06, 2025

Via Benzinga

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Via Benzinga

Topics Economy

Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday ↗

October 17, 2025

Via Benzinga

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗

October 17, 2025

The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months.

Via Investor's Business Daily

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Via Benzinga

'No Need To Sell' Martin Marietta Materials, Cramer Says: 'It's Just A Great Long-Term Hold' ↗

October 17, 2025

Wells Fargo's Timna Tanners initiated coverage on Martin Marietta Materials with an Equal-Weight rating and announced a price target of $620.

Via Benzinga

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗

October 17, 2025

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Via Stocktwits

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug ↗

September 11, 2025

Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 11, 2025

Via Benzinga

Aon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 10, 2025

Via Benzinga

This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

August 15, 2025

Via Benzinga

Revolution Medicines Inc (NASDAQ:RVMD) Reports Q2 2025 Earnings Miss, Shares Drop 4.5% After-Hours ↗

August 06, 2025

Revolution Medicines (RVMD) missed Q2 2025 revenue and EPS estimates, reporting $0 revenue and a -$1.31 loss. Shares dropped 4.5% amid investor concerns, despite progress in Phase 3 trials for...

Via Chartmill

Topics Earnings

This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

July 15, 2025

Via Benzinga

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

June 30, 2025

From Summit Therapeutics Inc.

Via Business Wire

Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds ↗

June 24, 2025

Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.

Via Benzinga

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma ↗

June 24, 2025

Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured...

Via Stocktwits

Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday ↗

May 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 07, 2025

Via Benzinga

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? ↗

April 28, 2025

Revolution Medicines shared Phase 1 data showing zoldonrasib's acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.